Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
5
×
fda
5
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
5
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
amgen
drugs
teva pharmaceutical
abbvie
astrazeneca
biogen
bristol-myers squibb
calcitonin gene-related peptide
cancer
cancer immunotherapy
What
drug
5
×
fda
approval
bio
class
companies
migraine
new
roundup
won
administration
alzheimer’s
amgen
angry
annual
anti
approved
arguments
assessed
attention
benefited
big
biotech
candidates
commercialized
communities
competitors
conference
decades
despite
developed
digital
disease
drugs
epidemic
esmo
europe
fatty
fear
frenzied
Language
Current search:
fda
×
drug
×
" seattle blog main "
×
" eli lilly "
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
